| 2026 |
| 03/06 | 5,560 | 5,688 | 5,555 | 5,687 | +0.99% | 4,179,700 | 9兆484億 | +1.43% |
| 03/05 | 5,708 | 5,727 | 5,616 | 5,631 | +0.41% | 4,650,300 | 8兆9593億 | +0.86% |
| 03/04 | 5,608 | 5,639 | 5,562 | 5,608 | -2.08% | 5,848,200 | 8兆9227億 | +0.81% |
| 03/03 | 5,744 | 5,790 | 5,681 | 5,727 | -1.16% | 4,834,800 | 9兆1121億 | +3.34% |
| 03/02 | （IR情報）16:00 真性多血症に対するファースト・イン・クラスの治療薬となる可能性を有するrusfertideの米国FDAによる新薬承認申請受理および優先審査指定 |
| 03/02 | 5,765 | 5,806 | 5,715 | 5,794 | -0.43% | 4,193,100 | 9兆2187億 | +5% |
| 02/27 | 5,725 | 5,832 | 5,716 | 5,819 | +1.54% | 6,683,400 | 9兆2585億 | +6.05% |
| 02/26 | 5,769 | 5,800 | 5,731 | 5,731 | -1.22% | 5,181,000 | 9兆1184億 | +5.1% |
| 02/25 | 5,844 | 5,848 | 5,736 | 5,802 | -0.28% | 4,863,700 | 9兆2314億 | +6.91% |
| 02/24 | 5,839 | 5,840 | 5,705 | 5,818 | +0.48% | 4,169,500 | 9兆2569億 | +7.76% |
| 02/20 | 5,800 | 5,806 | 5,755 | 5,790 | -0.43% | 4,349,100 | 9兆2118億 | +7.84% |
| 02/19 | 5,730 | 5,830 | 5,694 | 5,815 | +0.1% | 5,527,000 | 9兆2515億 | +8.81% |
| 02/18 | 5,611 | 5,809 | 5,607 | 5,809 | +4.53% | 7,302,600 | 9兆2420億 | +9.23% |
| 02/17 | 5,555 | 5,582 | 5,524 | 5,557 | +0.4% | 2,877,200 | 8兆8411億 | +5.13% |
| 02/16 | 5,640 | 5,642 | 5,530 | 5,535 | -1.41% | 3,806,800 | 8兆8061億 | +5.09% |
| 02/13 | 5,650 | 5,650 | 5,574 | 5,614 | +0.09% | 5,177,800 | 8兆9318億 | +6.95% |
| 02/12 | 5,602 | 5,616 | 5,563 | 5,609 | +0.5% | 4,501,600 | 8兆9238億 | +7.39% |
| 02/10 | （IR情報）17:00 米国FDAによるナルコレプシータイプ1に対するファースト・イン・クラスの治療となる可能性を有するoveporexton(TAK-861)の新薬承認申請受理および優先審査指定 |
| 02/10 | 5,550 | 5,613 | 5,530 | 5,581 | +1.4% | 5,033,900 | 8兆8793億 | +7.43% |
| 02/09 | 5,640 | 5,640 | 5,491 | 5,504 | -0.24% | 5,755,300 | 8兆7567億 | +6.5% |
| 02/06 | 5,531 | 5,548 | 5,465 | 5,517 | -1.34% | 4,868,100 | 8兆7774億 | +7.29% |
| 02/05 | 5,515 | 5,616 | 5,441 | 5,592 | +1.9% | 6,752,600 | 8兆8968億 | +9.28% |
| 02/04 | 5,467 | 5,494 | 5,437 | 5,488 | +1.27% | 4,891,900 | 8兆7313億 | +7.86% |
| 02/03 | 5,399 | 5,467 | 5,372 | 5,419 | +1.44% | 5,962,100 | 8兆6215億 | +7.03% |
| 02/02 | 5,375 | 5,401 | 5,315 | 5,342 | +1.91% | 6,465,400 | 8兆4990億 | +5.97% |
| 01/30 | 5,226 | 5,328 | 5,213 | 5,242 | +1.73% | 8,948,500 | 8兆3399億 | +4.42% |
| 01/29 | （IR情報）15:30 2026年3月期第3四半期決算短信〔IFRS〕(連結) |
| 01/29 | 5,112 | 5,154 | 5,085 | 5,153 | +1.4% | 6,221,200 | 8兆1983億 | +3.1% |
| 01/28 | 5,103 | 5,125 | 5,059 | 5,082 | -0.94% | 4,706,100 | 8兆854億 | +2.13% |
| 01/27 | 5,090 | 5,145 | 5,059 | 5,130 | +0.81% | 4,939,200 | 8兆1617億 | +3.59% |
| 01/26 | 5,050 | 5,118 | 5,046 | 5,089 | -0.53% | 4,177,700 | 8兆965億 | +3.31% |
| 01/23 | 5,078 | 5,124 | 5,034 | 5,116 | +1.77% | 4,631,200 | 8兆1394億 | +4.34% |
| 01/22 | 5,053 | 5,064 | 5,002 | 5,027 | +1.07% | 5,853,000 | 7兆9978億 | +3.05% |
| 01/21 | 5,015 | 5,062 | 4,956 | 4,974 | -1.74% | 6,369,600 | 7兆9135億 | +2.45% |
| 01/20 | （IR情報）16:45 (訂正)尋常性乾癬を対象としたザソシチニブ1日1回経口投与で皮膚病変の改善をもたらし治療の新時代を切り開く可能性を示した画期的な第3相臨床試験データ |
| 01/20 | 5,086 | 5,100 | 5,030 | 5,062 | -0.86% | 5,335,500 | 8兆535億 | +4.69% |
| 01/19 | 5,070 | 5,106 | 5,048 | 5,106 | +0.65% | 3,666,200 | 8兆1235億 | +6.11% |
| 01/16 | 5,101 | 5,122 | 5,034 | 5,073 | -1.99% | 4,985,200 | 8兆710億 | +5.97% |
| 01/15 | 5,215 | 5,230 | 5,152 | 5,176 | +0.5% | 5,400,000 | 8兆2349億 | +8.67% |
| 01/14 | 5,070 | 5,196 | 5,068 | 5,150 | +2.59% | 7,101,100 | 8兆1935億 | +8.83% |
| 01/13 | 5,129 | 5,153 | 5,020 | 5,020 | -1.18% | 7,292,300 | 7兆9867億 | +6.7% |
| 01/09 | 5,065 | 5,098 | 5,019 | 5,080 | -0.14% | 5,141,400 | 8兆822億 | +8.5% |
| 01/08 | 4,999 | 5,089 | 4,987 | 5,087 | +2.73% | 6,317,000 | 8兆933億 | +9.21% |
| 01/07 | 4,913 | 4,975 | 4,883 | 4,952 | +0.79% | 5,151,500 | 7兆8785億 | +6.84% |
| 01/06 | 4,889 | 4,919 | 4,863 | 4,913 | -0.06% | 4,707,800 | 7兆8165億 | +6.41% |
| 01/05 | 4,880 | 4,955 | 4,876 | 4,916 | +1.68% | 4,844,000 | 7兆8212億 | +6.87% |
| 2025 |
| 12/30 | 4,900 | 4,915 | 4,835 | 4,835 | -1.45% | 3,622,800 | 7兆6924億 | +5.45% |
| 12/29 | 4,884 | 4,925 | 4,878 | 4,906 | +0.74% | 4,637,900 | 7兆8053億 | +7.38% |
| 12/26 | 4,832 | 4,870 | 4,832 | 4,870 | +0.21% | 3,142,700 | 7兆7481億 | +7.01% |
| 12/25 | 4,860 | 4,868 | 4,821 | 4,860 | 0% | 2,360,300 | 7兆7322億 | +7.19% |
| 12/24 | 4,843 | 4,879 | 4,827 | 4,860 | +0.77% | 4,761,700 | 7兆7322億 | +7.62% |
| 12/23 | 4,712 | 4,823 | 4,712 | 4,823 | +2.97% | 7,388,300 | 7兆6733億 | +7.3% |
| 12/22 | 4,645 | 4,686 | 4,618 | 4,684 | +1.74% | 5,752,100 | 7兆4521億 | +4.62% |
| 12/19 | 4,612 | 4,678 | 4,604 | 4,604 | +2.65% | 12,000,500 | 7兆3248億 | +3.04% |
| 12/18 | （IR情報）17:00 尋常性乾癬を対象としたザソシチニブ1日1回経口投与で皮膚病変の改善をもたらし治療の新時代を切り開く可能性を示した画期的な第3相臨床試験データ |
| 12/18 | 4,500 | 4,529 | 4,485 | 4,485 | -0.11% | 4,073,100 | 7兆1355億 | +0.58% |
| 12/17 | 4,510 | 4,533 | 4,472 | 4,490 | -0.62% | 3,351,000 | 7兆1435億 | +0.85% |
| 12/16 | 4,518 | 4,531 | 4,492 | 4,518 | +0.83% | 4,543,700 | 7兆1880億 | +1.73% |
| 12/15 | 4,485 | 4,510 | 4,468 | 4,481 | +0.74% | 4,406,800 | 7兆1292億 | +1.2% |
| 12/15 | （空売り報告）JPM Securities Japan Co Ltd. 7,656,826株（0.48%）-0.02%義務消失 |
| 12/12 | 4,441 | 4,482 | 4,424 | 4,448 | -0.51% | 5,310,800 | 7兆767億 | +0.72% |
| 12/12 | （空売り報告）JPM Securities Japan Co Ltd. 7,980,567株（0.5%）再IN |
| 12/11 | 4,476 | 4,485 | 4,466 | 4,471 | -0.27% | 2,422,300 | 7兆1132億 | +1.5% |
| 12/10 | 4,457 | 4,494 | 4,452 | 4,483 | -0.27% | 3,079,900 | 7兆1323億 | +2.05% |
| 12/10 | （空売り報告）Barclays Bank PLC 15,441,897株（0.97%）-0.13% |
| 12/09 | 4,459 | 4,495 | 4,441 | 4,495 | +0.81% | 3,123,400 | 7兆1514億 | +2.58% |
| 12/08 | 4,440 | 4,459 | 4,408 | 4,459 | +1.11% | 2,521,300 | 7兆942億 | +2.08% |
| 12/08 | （IR情報）8:45 Protagonist Therapeutics社との、真性多血症におけるヘマトクリット値の持続的なコントロールを示したrusfertide長期データの第67回ASH年次総会での発表 |
| 12/05 | 4,443 | 4,462 | 4,400 | 4,410 | -1.41% | 3,004,400 | 7兆162億 | +1.15% |
| 12/04 | 4,434 | 4,473 | 4,411 | 4,473 | +0.43% | 3,370,300 | 7兆1164億 | +2.76% |
| 12/04 | （空売り報告）JPM Securities Japan Co Ltd. 7,852,625株（0.49%）-0.01%義務消失 |
| 12/03 | 4,440 | 4,458 | 4,426 | 4,454 | -0.4% | 3,408,700 | 7兆862億 | +2.49% |
| 12/03 | （空売り報告）JPM Securities Japan Co Ltd. 7,964,868株（0.5%）再IN |
| 12/02 | 4,454 | 4,478 | 4,441 | 4,472 | -0.82% | 3,913,800 | 7兆1148億 | +2.97% |
| 12/01 | 4,475 | 4,509 | 4,464 | 4,509 | +0.07% | 3,739,600 | 7兆1737億 | +3.99% |
| 11/28 | （IR情報）17:00 第149期(中間期)事業活動のご報告 |
| 11/28 | 4,461 | 4,506 | 4,451 | 4,506 | +0.54% | 2,855,000 | 7兆1689億 | +4.14% |
| 11/27 | 4,496 | 4,528 | 4,474 | 4,482 | -1.17% | 2,717,400 | 7兆1307億 | +3.8% |
| 11/26 | 4,496 | 4,549 | 4,492 | 4,535 | +1.73% | 6,345,600 | 7兆2151億 | +5.22% |
| 11/25 | 4,490 | 4,499 | 4,451 | 4,458 | +0.47% | 4,632,200 | 7兆926億 | +3.75% |
| 11/21 | 4,431 | 4,459 | 4,417 | 4,437 | -0.31% | 10,109,100 | 7兆592億 | +3.5% |
| 11/20 | 4,392 | 4,473 | 4,384 | 4,451 | +0.93% | 4,822,800 | 7兆814億 | +4.04% |
| 11/19 | 4,380 | 4,415 | 4,369 | 4,410 | +1.47% | 4,530,000 | 7兆162億 | +3.33% |
| 11/18 | 4,393 | 4,400 | 4,346 | 4,346 | -0.59% | 4,407,600 | 6兆9144億 | +2.02% |
| 11/17 | 4,373 | 4,416 | 4,361 | 4,372 | -1.6% | 3,245,900 | 6兆9557億 | +2.75% |
| 11/14 | 4,388 | 4,443 | 4,354 | 4,443 | +1.44% | 6,063,400 | 7兆687億 | +4.44% |
| 11/13 | 4,327 | 4,380 | 4,324 | 4,380 | +1.55% | 4,411,300 | 6兆9685億 | +3.06% |
| 11/12 | 4,350 | 4,379 | 4,309 | 4,313 | +2.08% | 6,094,400 | 6兆8619億 | +1.48% |
| 11/11 | 4,201 | 4,232 | 4,191 | 4,225 | +1.03% | 3,569,100 | 6兆7219億 | -0.63% |
| 11/10 | 4,210 | 4,210 | 4,172 | 4,182 | +0.05% | 4,297,400 | 6兆6535億 | -1.67% |
| 11/07 | 4,208 | 4,224 | 4,172 | 4,180 | -0.26% | 3,620,500 | 6兆6503億 | -1.83% |
| 11/06 | 4,150 | 4,213 | 4,148 | 4,191 | +0.7% | 3,467,400 | 6兆6678億 | -1.64% |
| 11/05 | 4,199 | 4,225 | 4,141 | 4,162 | -0.81% | 6,232,000 | 6兆6216億 | -2.44% |
| 11/04 | 4,222 | 4,224 | 4,158 | 4,196 | +1.04% | 5,274,700 | 6兆6757億 | -1.73% |
| 10/31 | 4,138 | 4,188 | 4,102 | 4,153 | -2.44% | 10,646,300 | 6兆6073億 | -2.97% |
| 10/30 | （IR情報）15:40 通期業績予想(IFRS)の修正に関するお知らせ |
| 10/30 | （IR情報）15:40 2026年3月期第2四半期(中間期)決算短信〔IFRS〕(連結) |
| 10/30 | 4,237 | 4,257 | 4,223 | 4,257 | +0.54% | 4,755,900 | 6兆7728億 | -0.82% |
| 10/29 | 4,302 | 4,324 | 4,234 | 4,234 | -1.58% | 3,759,800 | 6兆7362億 | -1.53% |
| 10/28 | 4,368 | 4,369 | 4,302 | 4,302 | -1.53% | 3,631,600 | 6兆8444億 | -0.16% |
| 10/27 | 4,325 | 4,370 | 4,318 | 4,369 | +1.7% | 4,537,800 | 6兆9510億 | +1.23% |
| 10/24 | 4,320 | 4,327 | 4,291 | 4,296 | +0.19% | 3,155,900 | 6兆8348億 | -0.53% |
| 10/23 | 4,302 | 4,303 | 4,272 | 4,288 | -0.14% | 2,750,800 | 6兆8221億 | -0.83% |
| 10/22 | 4,281 | 4,303 | 4,277 | 4,294 | +0.49% | 2,734,800 | 6兆8316億 | -0.85% |
| 10/21 | 4,248 | 4,290 | 4,240 | 4,273 | +1.21% | 3,355,500 | 6兆7982億 | -1.52% |
| 10/20 | 4,230 | 4,250 | 4,222 | 4,222 | +0.74% | 2,913,500 | 6兆7171億 | -2.9% |
| 10/17 | 4,213 | 4,219 | 4,191 | 4,191 | -0.47% | 3,072,000 | 6兆6678億 | -3.9% |
| 10/16 | 4,236 | 4,236 | 4,201 | 4,211 | +0.31% | 3,232,200 | 6兆6996億 | -3.73% |
| 10/15 | 4,190 | 4,227 | 4,189 | 4,198 | -0.71% | 4,179,400 | 6兆6789億 | -4.42% |
| 10/14 | 4,197 | 4,253 | 4,180 | 4,228 | +0.14% | 6,044,400 | 6兆7266億 | -4.06% |
| 10/10 | 4,288 | 4,294 | 4,219 | 4,222 | -2.63% | 5,953,500 | 6兆7171億 | -4.46% |
| 10/09 | 4,315 | 4,353 | 4,310 | 4,336 | -0.46% | 4,100,500 | 6兆8985億 | -2.12% |
| 10/08 | 4,420 | 4,434 | 4,345 | 4,356 | -0.11% | 4,380,500 | 6兆9303億 | -1.85% |
| 10/07 | 4,355 | 4,369 | 4,336 | 4,361 | -0.07% | 4,526,100 | 6兆9382億 | -1.82% |
| 10/01 | （IR情報）22:00 細胞療法の研究に関する最新情報 |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
